Colinz Laboratories Ltd

Colinz Laboratories Ltd

$COLINZPharmaceuticalsBSE

Colinz Laboratories Ltd (COLINZ) last traded at ₹71.1, a market capitalisation of ₹8.96 crore, on a P/E of 17.9. Over the past 52 weeks the stock has ranged between ₹36.1 and ₹87.9. Colinz Laboratories Ltd last reported results for the quarter ended Jun 2026, with sales of ₹1.24 crore and net profit of ₹2.4 crore. Colinz Laboratories Ltd’s annual general meeting is scheduled for 22 Sept 2026. Figures are as of 25 Aug 2026 and are not real time.

Colinz Laboratories Ltd share price and key metrics

Current price
₹71.1
Market cap
₹8.96 cr
Stock P/E
17.9
Book value
₹39.9
ROE
5.23%
ROCE
7.20%
Dividend yield
0.00%
52w high / low
87.9/36.1

Metrics as of 25 Aug 2026. Not real time.

Colinz Laboratories Ltd quarterly results

In the quarter ended Jun 2026, sales were ₹1.24 cr, down 21.0% from ₹1.57 cr a year earlier. Net profit was ₹2.4 cr, up 1900.0% year on year.

Colinz Laboratories Ltd consolidated quarterly results, figures in ₹ crore
₹ croreSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales1.861.471.451.571.391.431.751.24
Expenses1.691.41.351.441.311.331.661.18
Operating profit0.170.070.10.130.080.10.090.06
OPM %9.14%4.76%6.90%8.28%5.76%6.99%5.14%4.84%
Other income0.080.080.080.080.160.080.172.89
Interest0.010.010.020.010.010.010.010.01
Depreciation0.030.030.030.040.040.040.040.04
Profit before tax0.210.110.130.160.190.130.212.9
Tax %23.81%45.45%-23.08%25.00%26.32%30.77%19.05%17.24%
Net profit0.160.050.150.120.140.080.172.4
EPS (₹)0.640.200.600.480.560.320.679.53

Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.

Colinz Laboratories Ltd annual results

Colinz Laboratories Ltd annual profit and loss, figures in ₹ crore
₹ croreMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales6.166.977.157.036.536.145.81
Operating profit0.340.590.630.540.490.420.33
OPM %5.52%8.46%8.81%7.68%7.50%6.84%5.68%
Net profit0.210.340.460.490.50.512.79
EPS (₹)0.460.741.831.951.982.0211.08

TTM is the trailing twelve months to the most recent quarter.

Colinz Laboratories Ltd growth and returns

Compounded Sales Growth
10 Years
-3%
5 Years
0%
3 Years
-5%
TTM
-9%
Compounded Profit Growth
10 Years
19%
5 Years
19%
3 Years
2%
TTM
4%
Stock Price CAGR
10 Years
20%
5 Years
34%
3 Years
21%
1 Year
72%
Return on Equity
10 Years
4%
5 Years
5%
3 Years
5%
Last Year
5%

Colinz Laboratories Ltd shareholding pattern

Promoters held 50.60% at Jun 2026, down from 66.00% at Jun 2025.

Colinz Laboratories Ltd shareholding pattern by quarter, in percent
% heldSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters66.00%66.00%66.00%66.00%66.00%66.00%66.00%50.60%
Public34.00%33.99%33.99%34.00%33.99%34.00%34.00%49.39%
No. of shareholders3,1163,2023,2163,2383,2723,2123,2503,174

As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.

When is Colinz Laboratories Ltd’s AGM?

Colinz Laboratories Ltd’s annual general meeting is scheduled for 22 Sept 2026.

  • AGM40th AGM, adoption of financial statements, re-appointment of director, and appointment of Mrs. Vijaya Mani

See the full results calendar for every Indian company reporting in the next 30 days.

Colinz Laboratories Ltd corporate filings

  • Dear Sir, Pursuant to Regulation 34(1) and Regulation 30 of SEBI(LODR),Regulations ,2015. Please find the attached our 40th Annual Report for the FY 2025-26. Kindly take the same on ....Otherslow impact
    Filing PDF

    Cruxal's analysis: Colinz Laboratories Ltd has submitted its 40th Annual Report for the financial year…

    Read the full analysis
  • Dear Sir, AS requied under Regulation 42 of SEBI(LODR) , Regulations, 2015 we are submitting herewith the Intimation towards closure of Book from 15-09-2026 to 22-09-2026 for the purpose ....Corp. Actionlow impact
    Filing PDF

    Cruxal's analysis: Colinz Laboratories Ltd has notified the closure of its books from 15-09-2026 to…

    Read the full analysis
  • As required under SEBI (LODR)Regulaions, 2015 and Section 108 Companies Act 2013 Reas with Rule 20 and other Applicable Rules thereunder, we are submitting herewith 40th AGM Notice of our ....AGM/EGMlow impact
    Filing PDF

    Cruxal's analysis: Colinz Laboratories Limited has scheduled its 40th Annual General Meeting for 22nd…

    Read the full analysis
  • Saffron Capital Advisors Pvt Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Reminder Advertisement dated August 11, 2026 in relation to the open offer of Colinz Laboratories ....Company Updatehigh impact
    Filing PDF

    Cruxal's analysis: Colinz Laboratories Limited is the subject of an open offer by the Dugar family (Annjana…

    Read the full analysis
  • Saffron Capital Advisors Pvt Ltd ("Manager to the Open Offer") has submitted to BSE a copy of offer opening public announcement under Regulation 18(7) of the SEBI (SAST) Regulations, 2011, ....Company Updatehigh impact
    Filing PDF

    Cruxal's analysis: Colinz Laboratories Limited is the subject of an open offer by Annjana Dugar, Likhitta…

    Read the full analysis
  • Dear Sir, Submitting herewith the News Paper Clipping towards Advertiement in Newspaper towards submission of Declaration of Independent Directors Under SEBI SAST Regulation ,2011 and ....Company Updatelow impact
    Filing PDF

    Cruxal's analysis: Colinz Laboratories Ltd has submitted a newspaper clipping dated August 5, 2026…

    Read the full analysis

This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.

Track Colinz Laboratories Ltd

Cruxal reads every Colinz Laboratories Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.

Cruxal publishes market data and coverage for information only. Nothing here is investment advice.